Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

References

• Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017 June 8;376(23):2211–6. doi:https://doi.org/10.1056/NEJMoa1613210.
   PubMed Web of Science ®Google Scholar
• Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte K-W, Lehmann P, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016 June;17(6):757–67. doi:https://doi.org/10.1016/S1470-2045(16)00141-8.
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001 Sept 15;358(9285):866–69. doi:https://doi.org/10.1016/S0140-6736(01)06068-8.
   PubMed Web of Science ®Google Scholar
• Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler TK, Ellwanger U, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008 June;19(6):1195–201. Epub 2008 Feb 14. doi:https://doi.org/10.1093/annonc/mdn001.
   PubMed Web of Science ®Google Scholar
• McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RCG, Goydos JS, Beitsch PD, Urist MM, et al. Final results of the sunbelt melanoma trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon Alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol. 2016 Apr 1;34(10):1079–86. doi:https://doi.org/10.1200/JCO.2015.63.3776.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005 Oct 1;366(9492):1189–96. doi:https://doi.org/10.1016/S0140-6736(05)67482-X.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (NCCN Guidelines, US). Version 1.2021. Melanoma: Cutaneous; 2020 Nov 25. [accessed 2021 Feb]. www.NCCN.org.
   Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55. doi:https://doi.org/10.1056/NEJMoa1611299.
   PubMed Web of Science ®Google Scholar
• Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. doi:https://doi.org/10.1056/NEJMoa1709030.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. doi:https://doi.org/10.1056/NEJMoa1802357.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, et al. Nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;395(10236):1558–68. doi:https://doi.org/10.1016/S0140-6736(20)30417-7.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer. 2019;119:1–10. doi:https://doi.org/10.1016/j.ejca.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob -J-J, Chiarion-Sileni V, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465–77. doi:https://doi.org/10.1016/S1470-2045(20)30494-0.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk Stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J Clin Oncol. 2020;38(33):3925–36. doi:https://doi.org/10.1200/JCO.20.02110.
   PubMed Web of Science ®Google Scholar
• Elmore JG, Elder DE, Barnhill RL, Knezevich SR, Longton GM, Titus LJ, Weinstock MA, Pepe MS, Nelson HD, Reisch LM, et al. Concordance and reproducibility of melanoma staging according to the 7th vs 8th edition of the AJCC cancer staging manual. JAMA Netw Open. 2018 May;1(1):e180083. doi:https://doi.org/10.1001/jamanetworkopen.2018.0083.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York (NY): Springer; 2010.
   Google Scholar
• Amin MB, Edge SB, Greene FL, Byrd DR, eds. AJCC cancer staging manual. 8th ed. New York (NY): Springer; 2017.
   Google Scholar
• Crocetti E, Stanganelli I, Mancini S, Vattiato R, Giuliani O, Ravaioli A, Balducci C, Falcini F, Pimpinelli N. Evaluation of the agreement between TNM 7th and 8th in a population-based series of cutaneous melanoma. JEADV. 2019;33:521–24. doi:https://doi.org/10.1111/jdv.15285.
   Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019 July;116:148–57. doi:https://doi.org/10.1016/j.ejca.2019.05.020.
   PubMed Web of Science ®Google Scholar
• Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020 Sept 17;383(12):1139–48. doi:https://doi.org/10.1056/NEJMoa2005493.
   PubMed Web of Science ®Google Scholar